Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ghulam Mufti

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Blood Advances|February 18, 2021
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signatureSamah Alimam, William Villiers, Richard Dillon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemiaFrancis Giles, David Rizzieri, Judith Karp, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 22, 2018
Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation StudySalyka Sengsayadeth, Myriam Labopin, Ariane Boumendil, et al.
Blood Advances|August 26, 2018
Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP studySalyka Sengsayadeth, Katie S Gatwood, Ariane Boumendil, et al.
Blood|July 15, 2011
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5qPierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
Haematologica|January 19, 2019
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantationNico Gagelmann, Diderik-Jan Eikema, Matthias Stelljes, et al.
Haematologica|November 5, 2017
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow TransplantationChristoph Schmid, Liesbeth C de Wreede, Anja van Biezen, et al.
Bone Marrow Transplantation|April 29, 2025
Outcomes of human leukocyte antigen matched sibling transplant from consanguineous versus non-consanguineous parents, a single center experienceRiad El Fakih, Mohamed I Sharif, Shaykhah Alotaibi, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Blood Advances|February 18, 2021
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signatureSamah Alimam, William Villiers, Richard Dillon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemiaFrancis Giles, David Rizzieri, Judith Karp, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 22, 2018
Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation StudySalyka Sengsayadeth, Myriam Labopin, Ariane Boumendil, et al.
Blood Advances|August 26, 2018
Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP studySalyka Sengsayadeth, Katie S Gatwood, Ariane Boumendil, et al.
Blood|July 15, 2011
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5qPierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
Haematologica|January 19, 2019
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantationNico Gagelmann, Diderik-Jan Eikema, Matthias Stelljes, et al.
Haematologica|November 5, 2017
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow TransplantationChristoph Schmid, Liesbeth C de Wreede, Anja van Biezen, et al.
Bone Marrow Transplantation|April 29, 2025
Outcomes of human leukocyte antigen matched sibling transplant from consanguineous versus non-consanguineous parents, a single center experienceRiad El Fakih, Mohamed I Sharif, Shaykhah Alotaibi, et al.
Pageof 7